Related Experiment Videos
Splenectomy for complications of chronic granulocytic leukaemia
Insights
Splenectomy can benefit chronic granulocytic leukemia (C.G.L.) patients with hypersplenism or refractory phases. However, outcomes are poor for older patients or those with severe complications.
Area of Science:
- Hematology
- Oncology
Background:
- Chronic granulocytic leukemia (C.G.L.) often requires management of complications like hypersplenism and disease progression.
- Treatment decisions for C.G.L. must consider disease phase and patient-specific factors.
Purpose of the Study:
- To evaluate the efficacy of splenectomy in managing C.G.L. patients with refractory disease or hypersplenism.
- To identify patient subgroups and clinical conditions associated with unfavorable outcomes after splenectomy for C.G.L.
Main Methods:
- Retrospective analysis of 13 C.G.L. patients undergoing splenectomy.
- Assessment of treatment outcomes based on disease phase (chronic, refractory, myelofibrosis) and presence of hypersplenism.
Main Results:
- Splenectomy improved outcomes for 3 of 4 patients with hypersplenism.
- 5 of 8 patients with refractory C.G.L. showed positive responses to splenectomy.
- One case with myelofibrosis showed reduced transfusion needs but short survival.
Conclusions:
- Splenectomy is a viable option for C.G.L. with hypersplenism and potentially for refractory phases.
- Contraindications include advanced age (>65), comorbidities, rapid acute transformation, and severe bone marrow failure.
- Distinguishing early elective splenectomy from late-stage intervention is crucial for C.G.L. management.
Abstract:
13 patients with chronic granulocytic leukaemia (C.G.L.) which was unsatisfactorily controlled underwent splenectomy. 3 out of 4 patients with hypersplenism did well, as did 5 out of 8 patients in whom the C.G.L. had undergone metamorphosis to a refractory phase. In a case of C.G.L. complicated by severe myelofibrosis the need for transfusion was reduced but survival was short. Splenectomy should be considered when C.G.L. in its chronic phase is complicated by hypersplenism, and may be considered as a part of the treatment after C.G.L. has undergone metamorphosis to a refractory phase. However, a favourable outcome is unlikely for patients over 65 years, and in the presence of coexistent illnesses, rapidly progressive metamorphosis to an acute phase, or severe bone-marrow failure from any cause. In C.G.L., elective splenectomy early in the chronic phase must be clearly distinguished from splenectomy performed at a later stage when the disease is not well controlled.